Urinary excretion of liver-type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis

Clin Chim Acta. 2012 Jan 18;413(1-2):187-91. doi: 10.1016/j.cca.2011.09.018. Epub 2011 Sep 17.


Background: To evaluate the value of basal urinary L-FABP (uL-FABP) excretion as a prognostic indicator of the progression of kidney function impairment in patients with chronic glomerulonephritis (CGN).

Methods: One hundred twenty-three patients with newly diagnosed, biopsy-proven primary CGN were included. In all patients, and in 28 healthy subjects, uL-FABP was measured using an ELISA. Risk factors of the progression of kidney function were evaluated. The patients were in follow-up for at least 5 years.

Results: uL-FABP in the patients with CGN (76.58±17.3 μg/g.cr) was greater than in the healthy subjects. A significant positive correlation between uL-FABP and proteinuria (R=0.501, P<0.01), serum creatinine (R=0.601, P<0.01) were found. Kaplan-Meier analysis revealed that uL-FABP >76.58 μg/g.cr predicts progression of renal function. The cut off values for L-FABP at 119.8 μg/g.cr was found to be more sensitive, area under the curve (AUC) was 0.95.

Conclusion: Urinary L-FABP may be a useful clinical biomarker for monitoring chronic glomerular disease. Urinary L-FABP can help predict the progression of chronic glomerular disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / urine*
  • Chronic Disease
  • Enzyme-Linked Immunosorbent Assay
  • Fatty Acid-Binding Proteins / urine*
  • Female
  • Glomerulonephritis / physiopathology*
  • Glomerulonephritis / urine
  • Humans
  • Kidney / physiopathology*
  • Kidney Function Tests*
  • Male
  • Middle Aged


  • Biomarkers
  • Fatty Acid-Binding Proteins